An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Nov 2017 Planned primary completion date changed from 30 Sep 2018 to 1 Nov 2018.
- 03 Apr 2017 Status changed from not yet recruiting to recruiting.
- 12 Jan 2017 New trial record